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Abstract 
Objective: Patients undergoing hemodialysis are repeatedly exposed to stress and pain from 
approximately 300 punctures per year to their arteriovenous fistula. This study was designed 
to measure pain associated with venepuncture during AVF cannulation and to compare the 
effectiveness of ethyl chloride vapocoolant spray, topical eutectic mixture of local anesthetics 
(EMLA) cream and placebo in controlling pain caused by venepuncture of arteriovenous fistula 
patients undergoing chronic hemodialysis.  
Methods: This randomized, placebo-controlled, crossover study, included 41 patients un-
dergoing conventional hemodialysis three times a week. First intervention was conducted as 
baseline pain assessment (control). In the three consecutive dialysis sessions, every patient 
randomly received 1) ethyl chloride vapocoolant spray, 2) EMLA, or 3) placebo cream before 
venepuncture. Pain perception was recorded by patients immediately after cannulation on a 
0-100 mm visual analogue scale (VAS). p<0.05 was considered as significant.  
Results: VAS scores presented a marked inter-individual variation during venepuncture. 
EMLA application resulted in significantly lower total pain scores compared to control and all 
other interventions (p<0.05). No patient experienced severe pain with EMLA or vapocoolant. 
The patients reported less moderate and severe pain with EMLA, and vapocoolant spray 
compared to control and placebo interventions. Moderate and severe pain scores were 
similar between EMLA and vapocoolant spray (p>0.05).  
Conclusion: Venipuncture for AVF cannulation causes mild to moderate pain in hemodialysis 
patients. Although local application of EMLA is more effective than in preventing venepunc-
ture pain, ethyl chloride vapocoolant is as effective as EMLA for preventing mild to moderate 
puncture pain in patients undergoing hemodialysis. 
Key  words:  Hemodialysis, arteriovenous  fistula,  venepuncture  pain,  vapocoolant  spray,  visual 
analogue scale 
Introduction 
Chronic  renal  failure  is  a  devastating  medical, 
social, and economic problem for both patients and 
their  families.  Hemodialysis  is  the  most  frequently 
used  renal  replacement  therapy  with  the  arteriove-
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nous fistula (AVF) being the gold standard for vas-
cular access in hemodialysis patients (1). The extra-
corporeal blood flow rate is achieved through venous 
puncture, most often via two needles, one for blood 
aspiration called the arterial needle, one for venous 
reinjection called the venous needle (2,3).  
Patients  with end-stage renal disease undergo-
ing hemodialysis are repeatedly exposed to stress and 
pain from approximately 300 punctures per year to 
their AVF. Considerable patient discomfort and stress 
can  be  associated  with  the  insertion  of  large-gauge 
needles into an AVF. Alleviation of this pain might 
improve their acceptance of the procedure and thus, 
their quality of life (1,4,5).  
Previous  research  has  shown  that  topical  local 
anesthetic  creams  are  effective  in  reducing  venous 
puncture pain during AVF cannulation (6,7). The eu-
tectic mixture of local anesthetics, EMLA was formu-
lated to penetrate intact skin. EMLA significantly re-
duces  puncture  pain  and  represents  an  acceptable 
alternate  method  for  topical  anesthesia  in  venous 
cannulation  (8).  Immediate  topical  analgesia  is  pro-
vided  based  on  the  chilling  effect  of  evaporation, 
which is attained by spraying the determined surface 
with volatile liquid sprays (e.g. ethyl chloride, fluo-
rohydrocarbon) (6,9). Rapid evaporation of the vola-
tile liquid  spray from the  skin surface causes a de-
crease in temperature and results in temporary inter-
ruption of pain sensation, possibly through desensi-
tization of pain receptors or activation of ion channels 
involved in pain transmission. Page et al. (10) have 
demonstrated that topical vapocoolant sprays such as 
ethyl chloride are effective in reducing the pain dur-
ing emergent venous punctures. There are no studies 
assessing the efficacy vapocoolant sprays in hemodi-
alysis  patients.  Our  hypothesis  is  that  vapocoolant 
spray would be more efficacious than EMLA cream. 
The primary aim of this study was to assess the 
effectiveness  of  ethyl  chloride  vapocoolant  spray, 
topical EMLA cream and placebo in controlling pain 
caused by venepuncture of arteriovenous fistula pa-
tients undergoing chronic hemodialysis. The second-
ary aim was undertaken to measure pain associated 
with venepuncture during AVF cannulation.  
Methods 
This randomized, placebo-controlled, crossover 
study received approval from the Selcuk University 
Local Research Ethics Committee and all subjects gave 
written  informed  consent  before  participation.  The 
study included 41 patients undergoing conventional 
hemodialysis  three  times  a  week.  Eligible  patients 
were adults 18 yr of age or older of any gender who 
did not meet any of the following exclusion criteria: 
known  allergies  or  sensitivities  to  lidocaine,  prilo-
caine, or other local anesthetic; damaged, denuded, or 
broken skin at the designated site; concomitant use of 
an analgesic within the previous 24 h; or previous use 
of lidocaine/ prilocaine cream. 
Before  the  first  intervention,  the  patients  were 
informed about the study drugs and on how to use 
the visual analogue scale (VAS) for pain assessment. 
First intervention was conducted as baseline pain as-
sessment  (control);  venepuncture  was  performed 
without any intervention and pain score was assessed. 
In the three consecutive dialysis sessions, every pa-
tient  randomly  received  one  of  the  following  inter-
vention only once before venepuncture: 1) ethyl chlo-
ride  vapocoolant  spray  (IGS  aerosols  GMBH,  Ger-
many), 2) Eutectic mixture of 2.5% lidocaine and 2.5% 
prilocaine in an oil/water emulsion (EMLA cream® 
%5, Astra Zeneca, Istanbul, Turkey), or 3) placebo 
cream  (Ultrabase  cream;  Schering  Alman,  Istanbul, 
Turkey). 
The  vapocoolant  spray  was  sprayed  from  a 
pressure pack, at a distance of ~ 10 cm for 2 s. Liquid 
on the skin was allowed to evaporate for 10 s and the 
venepuncture was performed 20 s later after disinfec-
tion of the skin. Two ml of EMLA or placebo cream 
was applied to the two puncture sites under an oc-
clusion  dressing  according  to  the  product’s  instruc-
tions for use, 45-60 minutes before the insertion of the 
fistula needle. The cream was removed and the skin 
was disinfected before venepuncture. Venepunctures 
were performed with two 18G cannulas on the AV 
fistula. The same staff members performed the vene-
punctures.  
Degree of pain was expressed as a pain score. 
Pain  perception  was  recorded  by  patients  immedi-
ately  after  cannulation  on  a  VAS,  consisting  of  a 
non-graduated 100 mm horizontal line ranging from 
“0 = did not hurt at all” to “100 = as painful as it could 
be”. VAS scores over 30 were considered as moderate 
pain and over 54 mm were considered as severe pain 
(11). 
Safety and tolerability were evaluated based on 
the  frequency  of  adverse  events.  The  puncture  site 
was  inspected  before  and  2  h  after  cannulation  for 
redness,  pallor,  swelling,  damage  due  to  cold  and 
thrombophlebitis  and  local  skin  reactions  were  rec-
orded. The relation between pain scores and fistula 
age, gender, smoking habits, diabetes and hepatitis C 
virus (HCV) seropositivity were assessed. 
Descriptive  statistics  used  in  the  study  were 
frequencies,  percentage,  mean,  range,  and  standard 
deviation. The primary method of analysis involved 
using Chi square test whereby pair-wise comparisons 
were performed between the Vapocoolant group and Int. J. Med. Sci. 2011, 8 
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the  other  study  groups.  Further,  to  corroborate  re-
sults,  pair-wise  comparisons  between  median  VAS 
scores  were  also  tested  with  the  Mann–Whitney  U. 
Finally,  participants’  global  judgment  of  the  effec-
tiveness  of  the  allocated  treatment  was  compared 
with Chi square tests. p<0.05 was considered as sig-
nificant.  
Results 
Baseline demographic and clinical variables and 
primary nephropathies of the 41 maintenance hemo-
dialysis patients are presented in Table 1. Venepunc-
ture  pain  scores,  assessed  by  VAS  are  presented  in 
Table  2.  VAS  scores  presented  a  marked  in-
ter-individual variation during venepuncture, with a 
remarkable range from 0 mm to 77 mm and 0 mm to 
53mm in the Control/placebo and treatment groups 
respectively.  EMLA  application  resulted  in  signifi-
cantly lower total pain scores compared to control and 
all other interventions. No patient experienced severe 
pain with EMLA or vapocoolant spray. The patient 
reported less moderate and severe pain with EMLA, 
and vapocoolant spray compared to control and pla-
cebo interventions. Moderate pain scores were similar 
between EMLA and vapocoolant spray.  
No relationship was found between VAS scores 
and fistula age, gender, smoking or diabetes. In HCV 
positive patients, VAS scores of control, and placebo 
cream  were  significantly  lower  than  HCV  negative 
patients  (18.6±  20.4  vs.  31.2±16.6  and  20.4±20.1  vs. 
36.6±18.3 respectively) (p<0.05). 
All analgesic interventions were well tolerated. 
Only,  one  patient  who  used  EMLA  had  a  transient 
skin rash. 
Discussion 
Results  of  this  prospective  study  show  that 
compared to vapocoolant spray and placebo topical 
EMLA  application  45  to  60  min  prior  to  the  vene-
puncture  site  is  more  effective  in  preventing  vene-
puncture  pain.  Vapocoolant  spray  is  as  effective  as 
EMLA  for  preventing  mild  to  moderate  puncture 
pain.
 
Table 1. Demographic and clinical data of the 41 maintenance hemodialysis patients 
Age (Yr)  57.0±13.3 (32-82) 
Gender (males/ females)  51.2% / 48.8% 
Smoking  7 (17.1%) 
Diabetes  10 (24.4%) 
Dialysis durations (months)  70.5±57.4 (4-216) 
Age of fistula (months)  48.1±39.8 (3-180) 
Radiocephalic fistula/ brachiocephalic fistula  53.7% / 46.3% 
Fistula site: Right arm/ left arm  48.8% / 51.2% 
Nephropathy ethiology 
Unknown   17 (41.5 %) 
Diabetic nephropathy  10 (24.4 %) 
Hypertension  6 (14.6 %) 
Glomerulonephritis  4 (9.8 %) 
Amyloidosis  3 (7,3 %) 
Lupus nephritis   1 (2.4 %) 
Data are presented as mean± SD (range), percentage or number of patients (percentage) 
 
Table 2. Venipuncture pain scores, assessed by the visual analogue scale (VAS).  
  Control  Placebo   EMLA   Vapocoolant  
VAS  28.8±17.9 (0-75)  33.4±19.5 (0-77)  10.7±10.6 (0-44)*#§  14.0±12.4 (0-53)# § 
Moderate pain 
VAS> 30 mm 
20 (48.8%)  23 (56.1%)  4 (9.8%)#§  4 (9.8%)#§ 
Severe pain 
VAS> 54 mm 
5 (12.2%)  8 (19.5%)  0 (0%)#§  0 (0%)#§ 
VAS: 0mm-100mm. Data are presented as Mean± SD (range) or number of patients (percentage). *p=0.00 compared to vapocoolant, # p=0.00 
compared to control, § p=0.00 compared to placebo. 
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Venepuncture is one of the most frequently per-
formed medical procedures. Many patients on hemo-
dialysis repetitively experience pain and anxiety re-
lated  to  fistula  punctures  (12,13).  Repeated  AVF 
punctures lead to a considerable degree of pain, due 
to the caliber and length of the bevel of fistula needles 
(6,14). Our results show a wide range of variability in 
control and placebo pain scores. This is probably due 
to the differences in pain perception by individuals. 
Despite the fact that some patients do not experience 
any  pain,  the  significant  differences  between  the 
treatment and non-treatment scores in terms of severe 
and moderate pain displays the need for analgesia in 
patients undergoing venepuncture for AVF cannula-
tion. 
Human skin is protected by a corneous layer and 
is,  therefore  hardly  penetrable  to  local  anesthetics. 
McPhail et al (13) have found EMLA to be an effective 
topical anesthetic in preventing pain and alleviating 
anxiety  associated  with  needling.  In  the  study  of 
Watson  et  al  (9),  EMLA  was  highly  effective  com-
pared  to  placebo  and  lidocaine  injection  on  visual 
analogue and verbal rating scales for relieving pain 
during venepuncture. Although highly effective there 
are  some  disadvantages  for  clinical  EMLA  use.  Be-
cause the intact skin presents a significant barrier to 
available topical anesthetic preparations, to be effec-
tive EMLA requires application times of at least 45 to 
60 min before the painful procedure (15). Our study 
did not assess the time or cost effectiveness between 
the two proposed procedures but it is obvious that in 
terms of time vapocoolant spray is more practical for 
both the patient and the staff.  
Cutaneous side effects of EMLA associated with 
its  application  have  rarely  been  reported.  In  this 
study, both ethyl chloride and EMLA were well tol-
erated and there was nothing to distinguish between 
treatments regarding adverse events. In  our patient 
group, only one patient had allergic eruption over his 
brachial  arteriovenous  fistula  due  to  application  of 
EMLA.  The  lesions  resolved  after  topical  treatment 
with corticosteroids. In the study of Pérez-Pérez et al, 
one  patient  on  hemodialysis  developed  an  itchy 
eruption  over  his  brachial  arteriovenous  fistula, 
where EMLA was applied three times per week, prior 
to puncture for hemodialysis (16). Repeated exposure 
to EMLA might result with more skin rash. Lidocaine 
and prilocaine was considered as the primary allergen 
(16,17). Delayed sensitization was observed in 37% of 
patients with positive skin tests and 13.1% of patients 
which  had  previously  used  lidocaine–prilocaine 
cream (16).  
Vapocoolant  spray  is  claimed  to  provide  good 
patient satisfaction and staff convenience (8). Previous 
studies showed ethyl chloride to be effective in can-
nulation  pain  (18,19).  In  the  study  of  Page  et  al, 
vapocoolant was associated with greater cannulation 
success, less time to administer, and more staff con-
venience.  Unexpected  events  were  rare  and  minor 
(mild  pruritus  %4.4,  mild  pain  %1.1,  transient  ery-
thema  at  the  cannulation  site).  Some  studies  have 
displayed  disadvantages  for  vapocoolant  sprays;  in 
the study of Biro et al (8), spraying was found to have 
an additional negative component due to the rather 
painful cooling of the treated skin surface. Another 
disadvantage  of  cold  spray  is  its  short  duration  of 
analgesic action, whereas topical or local infiltration 
techniques persistent effect for up to 2h (8). We did 
not  encounter  any  of  the  disadvantages  of  the 
vapocoolant;  we  performed  the  venepuncture  30  s 
after  spraying  the  puncture  site.  Our  patients  were 
also comfortable during vapocoolant application and 
did not report any pain during cooling of the skin. 
Vapocoolant does have advantages over emla cream 
application  time  was  significantly  shorter  and  only 
involved  picking  up  and  shaking  the  can  and 
spraying for 2 s. EMLA needs to be applied at least 45 
minutes  before  the  intervention,  compared  with  30 
seconds  for  the  Vapocoolant  spray.  Although  we 
found that vapocoolant reduces total cannulation pain 
less than EMLA we are in the opinion that it is easier 
to use, has a shorter administration time which pro-
vides more staff and patient convenience.  
The  possible  vasoconstrictive  effects  of 
vapocoolant spray may be a concern for the patency 
of AVF. Prior to this study we conducted a prelimi-
nary  evaluation  with  pulsed  duplex-Doppler  ultra-
sonography  on  10  voluntary  healthy  adults  and  10 
dialysis  patients.  All  ultrasonographic  examinations 
were performed on Aplio XU unite (Toshiba Medical 
Systems,  Tustin,  Calif)  using  7.5  MHz  linear  trans-
ducer. The left arm brachial artery diameter (mm) and 
vascular flow volume (ml/min) of both groups were 
measured  in  neutral  position.  Following  the 
vapocoolant  spray  application,  measurements  were 
repeated after 1, 5 and 15 minutes. There was no sig-
nificant  difference  in  vessel  diameter  and  flow  vol-
ume after vapocoolant application in healthy adults 
and dialysis patients. 
Demographic  differences  may  affect  pain  per-
ception.  In  previous  studies,  AV  fistula  punc-
ture-related  pain  intensity  was  associated  with  the 
female  sex,  while  no  relationship  existed  with  the 
duration of fistula use, the educational qualification, 
or the age of the subjects (1). It has been reported in 
other literature that intensity of pain was significantly 
associated  with  female  gender,  older  age,  cigarette 
smoking (20,21). Our results were in accordance with Int. J. Med. Sci. 2011, 8 
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the study of Ingalls et al (22), there was no significant 
relationship regarding pain and age, gender, smoking 
history, percent of current smokers. 
As a conclusion, venipuncture for AVF cannula-
tion causes mild to moderate pain in a group of he-
modialysis  patients.  Although  local  application  of 
EMLA  is  more  effective  than  in  preventing  vene-
puncture pain, ethyl chloride vapocoolant is as effec-
tive as EMLA for preventing mild to moderate punc-
ture pain and is more convenient for clinical use. 
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